Intervention trial for determining recommendation effects of explaining detailed information regarding future cardiovascular risks on rate of visiting medical facilities for those who were found to have chronic diseases in medical check-up

Intervention trial for determining recommendation effects of explaining detailed information regarding future cardiovascular risks on rate of visiting medical facilities for those who were found to have chronic diseases in medical check-up - Next 10

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024692

Enrollment

6000

Registered

2016-12-01

Start date

2016-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Noncommunicable Diseases

Interventions

(a) Selection of examinees who fit the selection policy for research subjects. (b) In addition to the usual notification of the results of the medical checkups, send a letter notifying them that they

s result notification slip will be used to recommend medical examinations, as in the past.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) NIPPON DATA: Patients who have "Probability of death from cardiovascular disease within 10 years: 7-15% or more (2) Patients who meet the following conditions according to the comprehensive risk management chart: "Step 1c Determination of the need for referral to a specialist, etc." (a) Hypertension*: Grade II hypertension (systolic blood pressure 160 mmHg) (a) Hypertension*: Grade II hypertension (systolic blood pressure 160 mmHg, or diastolic blood pressure 100 mmHg) (b) Diabetes mellitus: HbA1c 6.5%*, fasting blood glucose 126mg/dL, or anytime blood glucose 200mg/dL) (c) Dyslipidemia: LDL-C 180mg/dL, HDL-C 30mg/dL, fasting TG 500mg/dL, nonHDL-C 210mg/dL, (d) Chronic kidney disease: severe proteinuria (2+ by the paper method), both proteinuria and hematuria positive (1+ by the paper method), eGFR<50mL/min/1.73m2 (60 in patients 40 years old, 40 in patients 70 years old with stable renal function) (e) Obesity: severe obesity (BMI 35)

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Improvement of weight, blood pressure, lipid, and glucose data after 1 year in the following subjects 1. NIPPON DATA: Patients who have a "probability of death from cardiovascular disease within 10 years: 7-15% or more 2. Patients who meet the following conditions based on the comprehensive risk management chart: "Step 1c: Determination of the need for referral to a specialist, etc." (a) Hypertension a. Hypertension: Grade II hypertension (systolic blood pressure 160 mmHg, or diastolic blood pressure 100 mmHg) b. Diabetes mellitus: HbA1c 6.5%, fasting blood glucose 126mg/dL, or anytime blood glucose 200mg/dL) c. Dyslipidemia: LDL-C 180mg/dL, HDL-C 30mg/dL, fasting TG 500mg/dL, nonHDL-C 210mg/dL, d. Chronic kidney disease: severe proteinuria (2+ by the paper method), both proteinuria and hematuria positive (1+ by the paper method), eGFR 50mL/min/1.73m2 (60 in patients 40 years old, 40 in patients 70 years old with stable renal function) e. Obesity: severe obesity (BMI 35)	—

Measure

Time frame

Improvement of weight, blood pressure, lipid, and glucose data after 1 year in the following subjects 1. NIPPON DATA: Patients who have a "probability of death from cardiovascular disease within 10 years: 7-15% or more 2. Patients who meet the following conditions based on the comprehensive risk management chart: "Step 1c: Determination of the need for referral to a specialist, etc." (a) Hypertension a. Hypertension*: Grade II hypertension (systolic blood pressure 160 mmHg, or diastolic blood pressure 100 mmHg) b. Diabetes mellitus: HbA1c 6.5%*, fasting blood glucose 126mg/dL, or anytime blood glucose 200mg/dL) c. Dyslipidemia: LDL-C 180mg/dL, HDL-C 30mg/dL, fasting TG 500mg/dL, nonHDL-C 210mg/dL, d. Chronic kidney disease: severe proteinuria (2+ by the paper method), both proteinuria and hematuria positive (1+ by the paper method), eGFR 50mL/min/1.73m2 (60 in patients 40 years old, 40 in patients 70 years old with stable renal function) e. Obesity: severe obesity (BMI 35)

—

Secondary

Measure	Time frame
Ratio of antihypertensive, antidiabetic, and antidyslipidemic drug use after 1 year	—

Countries

Japan

Contacts

Public ContactKiminori Kato

Graduate School of Medical and Dental Sciences Niigata University Department of Laboratory Medicine and Clinical Epidemiology for Prevention of Noncommunicable Diseas

kkato48@med.niigata-u.ac.jp+81-25-227-2117

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026